



**YONSEI**  
UNIVERSITY

# Imaging tools to assess surgical margins and pseudocapsule features before partial nephrectomy for small renal masses

Won Sik Ham,  
Department of Urology,  
Urological Cancer Center, Severance Hospital,  
Yonsei University College of Medicine

*Severance*






Fig. 1 - The contemporary anatomy of partial nephrectomy (PN).



# Simple tumor enucleation may not decrease oncologic outcomes for T1 renal cell carcinoma: A systematic review and meta-analysis

De-Hong Cao, M.D.<sup>1</sup>, Liang-Ren Liu, M.D.<sup>1</sup>, Yu Fang, M.D., Ping Tang, M.D.,  
Tao Li, M.D., YunJin Bai, M.D., Jia Wang, M.D.\*, Qiang Wei, M.D.\*

**Objective:** To evaluate the clinical efficacy and safety of simple tumor enucleation (TE) for clinical T1 renal cell carcinoma.

**Materials and methods:** A systematic search of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases was performed to identify all trials that compared TE and traditional partial nephrectomy (PN) for patients with clinical T1 renal cell carcinoma.

**Results:** A total of 7 studies involving 3,218 patients were identified and included in this meta-analysis. Compared with the PN group, the TE group had significantly shorter estimated operation times (mean difference [MD] = -21.93; 95% CI: -31.07 to -12.78;  $P < 0.001$ ), shorter warm ischemia times (MD = -1.96; 95% CI: -3.80 to -0.13;  $P = 0.04$ ), less blood loss (MD = -36.63; 95% CI: -57.49 to -15.77;  $P = 0.0006$ ), and lower surgical complication rates (odds ratio [OR] = 0.66; 95% CI: 0.47–0.92;  $P = 0.02$ ). Furthermore, there was no significant difference between the 2 groups in hospital stay duration (MD = -0.46; 95% CI: -0.93 to 0.02;  $P = 0.06$ ), changes in estimated glomerular filtration rate (MD = 3.35; 95% CI: -2.78 to 9.48;  $P = 0.28$ ), positive surgical margin rates (OR = 0.34; 95% CI: 0.10–1.14;  $P = 0.08$ ), and local recurrence rates (OR = 0.71; 95% CI: 0.24–2.06;  $P = 0.52$ ).

**Conclusion:** Compared to traditional PN, TE is an effective and safe treatment for T1 renal tumors, and TE appears to have acceptable early oncology outcomes. Owing to the limited number of clinical trials and the predominantly retrospective data on this subject, there is a need for properly designed studies to confirm our findings. © 2017 Elsevier Inc. All rights reserved.

REVIEW

# Positive surgical margins and local recurrence after simple enucleation and standard partial nephrectomy for malignant renal tumors: systematic review of the literature and meta-analysis of prevalence

Andrea MINERVINI<sup>1</sup>, Riccardo CAMPI<sup>1\*</sup>, Francesco SESSA<sup>1</sup>,  
Ithaar DERWEESH<sup>2</sup>, Jihad H. KAOUK<sup>3</sup>, Andrea MARI<sup>1</sup>, Koon H. RHA<sup>4</sup>,  
Maurizio SESSA<sup>5</sup>, Alessandro VOLPE<sup>6</sup>, Marco CARINI<sup>1</sup>, Robert G. UZZO<sup>7</sup>

**INTRODUCTION:** The definition of the safest width of healthy renal margin to achieve oncological efficacy and therefore of the safest resection technique (RT) during partial nephrectomy (PN) continues to be widely debated. The aim of this study is to evaluate the prevalence of positive surgical margins (PSM), loco-regional recurrence (LRR) and renal recurrence (RER) rates after simple enucleation (SE) and standard partial nephrectomy (SPN) for malignant renal tumors.


**EVIDENCE ACQUISITION:** A systematic review of the English-language literature was performed through August 2016 using the Medline, Web of Science and Embase databases according to the PRISMA criteria. A systematic review and meta-analysis was performed in those studies that defined the exact anatomical location of recurrence after PN.

**EVIDENCE SYNTHESIS:** Overall, 33 studies involving 11,282 patients were selected for quantitative analysis. At a median follow-up of 43 (SE) and 52 (SPN) months, the pooled estimates of the prevalence of PSMs, LRR and RER were 2.7% (95% CI: 1.5-4.6%,  $P < 0.001$ ) and 0.4% (95% CI: 0.1-2.2%,  $P = 0.018$ ), 2.0% (95% CI: 1.4-2.8%,  $P < 0.001$ ) and 0.9% (95% CI: 0.5-1.7%,  $P = 0.04$ ), 1.5% (95% CI: 0.9-2.3%,  $P = 0.001$ ) and 0.9% (95% CI: 0.5-1.7%,  $P = 0.40$ ) in patients undergoing SPN and SE, respectively.

**CONCLUSIONS:** Our systematic analysis and meta-analysis demonstrates that SE is noninferior to SPN regarding PSM, LRR and RER rates in patients undergoing PN for malignant renal tumors. Further studies using standardized reporting tools are needed to evaluate the role of resection techniques for oncologic outcomes after PN.


### Resection

Macroscopic margin,  
no visualisation of  
the tumour's contours




### Enucleoresection

Minimal margin,  
clear visualisation of the tumour's contours



### Enucleation

Only the pseudocapsule is seen,  
no additional overlying tissue



**Enucleation:**

Tumor resected along pseudocapsule without additional overlying tissue


**Enucleoresection:**

Minimal margin of parenchyma with tumor contour readily visible

**Resection:**

Tumor contour cannot be appreciated through resected parenchyma

**c:**  
capsulotomy



**For the *Surface* area:**

0 = Enucleation

1 = Enucleoresection/Resection

**For the *Intermediate* and *Base* areas:**

0 = Enucleation


1 = Enucleoresection

2 = Resection

Fig. 1 – Surface–intermediate–base (SIB) scoring system for standardized reporting of nephron-sparing surgery resection techniques.

# Renal tumor pseudocapsule

- Fibrous band of compressed renal parenchyma that isolates the tumor from the surrounding healthy renal parenchyma and provides a natural dissection plane during surgery



**Figure 1.** Microscopic investigation reveals clear cell RCC with intact pseudocapsule. Inferior portion exemplifies carcinoma isolated from superior portion of healthy parenchyma by pseudocapsule (*PC*). *NK*, normal kidney. *A*, reduced from  $\times 5$ . *B*, reduced from  $\times 10$ .

**Table 3.** Tumor PC and tumor-parenchyma interface by malignancy

	Benign	Malignant	p Value
No. pts (%)	13	111	—
No. PC (%):	12 (92)	107 (96)	0.4
Intrarenal	4 (31)	91 (82)	<0.001
Extrarenal	11 (84)	93 (85)	1
Mean $\pm$ SD PC thickness (mm):	0.3 (0.2)	0.7 (0.5)	0.05
Intrarenal	0.3 (0.2)	0.7 (0.5)	0.05
Extrarenal	0.3 (0.2)	0.7 (0.6)	0.03
No. overall PC invasion (%):	2 (15)	51 (45)	0.04
Intrarenal	0	36 (39)	0.3
Extrarenal	2 (18)	28 (30)	0.5
Mean $\pm$ SD clinical tumor size (cm)	3.1 (1.2)	4 (2.7)	0.3
Mean $\pm$ SD surgical margin width (mm)	6.4 (3.4)	3.8 (3.2)	0.017
Mean $\pm$ SD No. arterioles:			
3 mm or Less distant from tumor	2.3 (1.6)	2.8 (1.2)	0.046
Greater than 3 mm distant from tumor	1.8 (0.7)	2.8 (1.2)	0.006
Mean $\pm$ SD arteriolar diameter (mm):			
3 mm or Less distant from tumor	0.4 (0.1)	0.4 (0.1)	0.104
Greater than 3 mm distant from tumor	0.5 (0.2)	0.6 (0.2)	0.111



**Table 2.** Intrarenal and extrarenal PC presence and invasion by histological features

	Overall	Intrarenal PC (96 tumors)			
		Presence	p Value	Invasion	p Value
Mean $\pm$ SD malignant tumor size*	3.9 $\pm$ 2.6	3.9 $\pm$ 2.7	0.7	3.8 $\pm$ 2.4	0.95
No. malignancy pathological stage (%):†					
T1a	66 (59)	55 (57)	0.07	24 (25)	0.5
T1b	27 (24)	24 (25)		10 (10)	
T2	3 (2.7)	2 (2)		1 (1.04)	
T3a	6 (5.4)	5 (5.2)		0	
T3b	5 (4.5)	2 (2.1)		1 (1.04)	
T4	1 (0.9)	1 (1.04)		0	
No. tumor type (%):†					
Malignant	111 (90)	91 (82)	<0.001	36 (37.5)	0.1
Benign	13 (10)	4 (31)		0	
No. malignancy subtype (%):†					
Clear cell	77 (69)	70 (73)	<0.001	25 (26)	0.09
Chromophobe	12 (11)	6 (6)		1 (1.04)	
Papillary	16 (14)	12 (12.5)		8 (8)	
Other	6 (5)	3 (3.12)		2 (2.1)	
No. malignancy Fuhrman grade (%):†					
I/II	74 (67)	64 (68)	0.13	27 (28)	0.5
III/IV	37 (33)	27 (28)		9 (9.4)	

\* Continuous (Kruskal-Wallis test p values).

† Categorical (Fisher exact test p values).

# Bi- or triphasic contrast-enhanced CT

- Enhancement of >15–20 Hounsfield units (HU) is considered the most important indicator of malignancy and is best assessed in the nephrographic phase.
- The corticomedullary phase is used to assess the arterial system (number of renal arteries, feeding mass arteries)
- The urographic phase to assess proximity to and involvement of the renal collecting system
- **Pseudocapsule (PC) detection sensitivity 10-26%**

Radiographics 38:2021–2033, 2018

AJR Am J Roentgenol 166(5):1151–1155, 1996

AJR Am J Roentgenol 166(5):1151–1155, 1996

# Magnetic resonance imaging (MRI)

- Problem solving tool in patients with indeterminate CT scans (eg, for complex cystic lesions, very small masses, enhancement of 10–20 HU) or contrast medium allergies
- Better for detecting **perirenal fat invasion** and evaluating the **cranial and caudal extent of a venous thrombus in the IVC**, as well as delineating benign thrombus from tumor thrombus

# PC on MRI

- first described, in 1985, the PC on MRI, appearing as a **low-intensity band separating the tumor from the normal renal parenchyma or perirenal fat** on both T1 and T2 sequences
- **T2-weighted images**, however, were found to be the most sensitive for detecting the PC, interposed between the higher intensity of the tumor and normal renal parenchyma
- **PC detection sensitivity 54-93%**

Radiographics 38:2021–2033, 2018

AJR Am J Roentgenol 166(5):1151–1155, 1996

AJR Am J Roentgenol 166(5):1151–1155, 1996




<b><i>i</i>-Cap Score</b>	<b>Description</b>	<b>Representative Image</b>
1	Pseudocapsule is completely intact on the normal parenchyma side.	 <p>This image shows a cross-section of kidney tissue. At the top, a layer of normal kidney (NK) is visible. Below it is a thin, continuous layer of pseudocapsule (PC). The RCC is located below the PC, showing a distinct cellular morphology. Labels 'NK', 'PC', and 'RCC' are present.</p>
2	Pseudocapsule has either a focal absence or <100% infiltration of carcinoma into the PC but not into the normal parenchyma.	 <p>This row contains two images. The left image shows a focal area where the pseudocapsule (PC) is missing, with RCC cells present at the boundary. Labels include 'Focal PC Absence', 'PC', and 'RCC'. The right image shows RCC cells infiltrating through the pseudocapsule (PC) into the underlying tissue. Labels include 'NK', 'PC', and 'RCC Infiltration into PC'.</p>
3	Any degree of carcinoma infiltration completely through the PC and into the normal parenchyma.	 <p>This image shows the RCC completely breaching the pseudocapsule (PC) and invading the normal kidney parenchyma. Labels include 'RCC Invading Through PC', 'PC', and 'PC'.</p>

Figure 2. *i*-Cap scoring system. NK, normal kidney. PC, pseudocapsule. Reduced from  $\times 10$ .

# New classification system to standardize MRI report on PC status: MRI-Cap

- MRI-Cap 0: No visible hypointense rim surrounding the tumor on T2- and T1-weighted images
- MRI-Cap 1: Presence of a clearly identifiable, continuously intact, hypointense rim surrounding the lesion on T2-weighted images
- MRI-Cap 2: Presence of a PC, which appears focally interrupted but in the absence of an obvious infiltration beyond its boundaries assessed on T2-weighted images. No clear interruption visible on T1-weighted images
- MRI-Cap 3: Presence of PC which appears clearly interrupted and infiltrated assessed on both T2- and T1-weighted images

# Accuracy of magnetic resonance imaging to identify pseudocapsule invasion in renal tumors

Rocco Papalia<sup>1</sup>  · Valeria Panebianco<sup>2</sup> · Riccardo Mastroianni<sup>1</sup> · Maurizio Del Monte<sup>2</sup> · Emanuela Altobelli<sup>1</sup> · Eliodoro Faiella<sup>4</sup> · Francesco Rosario Grasso<sup>4</sup> · Mariangela Bellangino<sup>5</sup> · Giuseppe Simone<sup>6</sup> · Massimo Ciccozzi<sup>7</sup> · Silvia Angeletti<sup>8</sup> · Giulia D'ovidio<sup>2</sup> · Carlo Catalano<sup>2</sup> · Michele Gallucci<sup>3</sup> · Roberto Mario Scarpa<sup>1</sup> · Giovanni Muto<sup>9</sup>

**Table 2**  $\rho$  coefficient, sensitivity, specificity, PPV, NPV and AUC of MRI PC evaluation compared to i-Cap

	MRI-Cap 0 / i-Cap 0	MRI-Cap 1/ i-Cap 1	MRI-Cap 2 / i-Cap 2	MRI-Cap 3 / i-Cap 3	Global
$\rho$ coefficient	0.89 (IC95% 0.83–0.94)	0.75 (IC95% 0.60–0.84)	0.76 (IC95% 0.63–0.85)	0.87 (IC95% 0.79–0.92)	0.94 (IC95% 0.90–0.96)
Sensitivity	97.8%	77%	88%	94%	
Specificity	83.3%	95.5%	90%	95%	
PPV	95.8%	83.3%	79%	88%	
NPV	90.9%	93.5%	95%	97%	
AUC	0.91	0.86	0.89	0.94	

# Arterial spin labelling MRI for detecting pseudocapsule defects and predicting renal capsule invasion in renal cell carcinoma

H. Zhang<sup>a,†</sup>, Y. Wu<sup>b,†</sup>, W. Xue<sup>c</sup>, P. Zuo<sup>d</sup>, N. Oesingmann<sup>e</sup>, Q. Gan<sup>f</sup>, Z. Huang<sup>a</sup>, M. Wu<sup>a</sup>, F. Hu<sup>a</sup>, M. Kuang<sup>g</sup>, B. Song<sup>a,\*</sup>

**Table 3**

Two-by-two table for T2-weighted imaging (T2WI) versus the reference standard.

T2WI	Histopathology		Total
	+	-	
+	13	2	15
-	0	5	5
Total	13	7	20

+/-, Renal capsule invasion/not invasion.

**Table 4**

Two-by-two table for T2-weighted imaging (T2WI) + arterial spin labelling (ASL) versus the reference standard.

T2WI+ASL	Histopathology		Total
	+	-	
+	12	0	12
-	1	7	8
Total	13	7	20

+/-, Renal capsule invasion/not invasion.

	T2 WI	T2 WI+ASL
sensitivity	100%	92.3%
specificity	71.4%	100%
PPV	86.7%	100%
NPV	100%	87.5%



# Conclusion (I)

- MRI in patients with RCC should be indicated preferably when CT scan is unable to detect intact PC surrounding the entire tumor and simple enucleation is considered.

# Conclusion (II)

- The combination of **simple enucleation** and **minimally invasive renorrhaphy** could yield maximum renal function at postoperative follow-up.




Fig. 2 – Suture of the cortex. (A) The suture has been performed superficial enough in order to avoid the involvement of the arcuate arteries: the blood supply to the medullar parenchyma by the vasa recta is spared. (B) The suture has been deepened with involvement of the arcuate arteries and subsequent ischaemia of both the cortical and the medullar parenchyma.

# *Severance*

With the Love of God, Free Humankind from Disease and Suffering

